Recent advances of clinical researches on antibody-mediated rejection by targeting interleukin-6 and its receptor
10.3760/cma.j.cn421203-20230919-00097
- VernacularTitle:靶向IL-6及其受体治疗抗体介导的排斥反应的临床研究进展
- Author:
Jie DING
1
;
Yuting HU
;
Jiating WANG
;
Zhangfei SHOU
Author Information
1. 浙江中医药大学浙江树人学院，杭州 310053
- Keywords:
Kidney transplantation;
Rejection;
Interleukin-6;
Targeted therapy
- From:
Chinese Journal of Organ Transplantation
2023;44(12):759-763
- CountryChina
- Language:Chinese
-
Abstract:
Chronic kidney disease has been a global public health problem with a heavy disease burden.As a kidney replacement therapy, kidney transplantation(KT)has a higher long-term survival rate and quality-of-life as compared with dialysis.Antibody-mediated rejection(AMR)is a major complication after KT.Currently its core treatments are steroid hormones, plasma exchange and immunoglobulin.However, the effectiveness of new therapeutic agents such as anti-CD20 antibody and bortezomib has remained controversial.Despite these combination treatments, AMR is still a predominant cause of graft loss and it is imperative to seek novel effective treatments.Interleukin-6(IL-6)is a vital cytokine involved in the regulation of inflammation and the development, maturation and activation of T/B cells.Specifically targeting IL-6, ptolizumab and crazizumab are currently widely applied for managing AMR and blunting highly sensitized KT recipients.This review summarized the clinical applications of IL-6 for AMR.
